Production (Stage)
Avenue Therapeutics, Inc.
ATXI
$0.2088
-$0.0113-5.13%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.78% | 11.01% | -25.97% | -11.20% | -14.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.78% | -22.39% | -27.71% | -28.20% | 1.80% |
| Operating Income | 19.78% | 22.39% | 27.71% | 28.20% | -1.80% |
| Income Before Tax | -27.23% | -11.52% | 10.03% | 49.64% | 13.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.23% | -11.52% | 10.03% | 49.64% | 13.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -24.07% | -60.36% | -62.59% | -57.14% | -53.85% |
| Net Income | -27.61% | -12.29% | 9.33% | 49.56% | 12.71% |
| EBIT | 19.78% | 22.39% | 27.71% | 28.20% | -1.80% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 86.92% | 90.81% | 89.04% | 95.75% | 74.92% |
| Normalized Basic EPS | 85.29% | 90.30% | 92.22% | 98.26% | 74.86% |
| EPS Diluted | 89.06% | 85.04% | 82.94% | 91.08% | 70.03% |
| Normalized Diluted EPS | 85.29% | 90.30% | 92.22% | 98.26% | 74.86% |
| Average Basic Shares Outstanding | 620.65% | 816.63% | 932.43% | 707.34% | 511.50% |
| Average Diluted Shares Outstanding | 620.65% | 816.63% | 932.43% | 707.34% | 511.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |